A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
AGITG, TROG and NHMRC CTC
Accrual Target
120
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN@ctc.usyd.edu.au
Clinical Trial Registration
Related Post
18 September, 2024
TOPGEAR trial findings published in NEJM
18 September 2024: We’re thrilled to announce the release
11 September, 2024
Putting radiation medicine research on the world stage: 2024 ASM a resounding success
11 September 2024: Our 2024 Annual Scientific Meeting was
